Studies have shown that the interaction of PDCD1 and its ligand leads to impaired T-cell function and immune evasion by cancer cells; therefore, targeting PDCD1 and its ligand with inhibitory drugs leads to the restoration of T-cell immune function and antitumor activity [11]. Here, PDCD1 is linked to cancer.